Skip to main content
Erschienen in: Breast Cancer Research 5/2000

01.10.2000 | Commentary

Metastases: the glycan connection

verfasst von: Christine Couldrey, Jeffrey E Green

Erschienen in: Breast Cancer Research | Ausgabe 5/2000

Einloggen, um Zugang zu erhalten

Abstract

An association between protein glycosylation and tumorigenesis has been recognized for over 10 years. Associations linking the importance of glycosylation events to tumor biology, especially the progression to metastatic disease, have been noted over many years, Recently, a mouse model in which β1,6-N-acetylglucosaminyltransferase V (a rate-limiting enzyme in the N-glycan pathway) has been knocked out, was used to demonstrate the importance of glycosylation in tumor progression. By crossing mice lacking this enzyme with a transgenic mouse model of metastatic breast cancer, metastatic progression of the disease was dramatically reduced. These experiments provide in vivo evidence for the role of N-linked glycosylation in metastatic breast cancer and have significant implications for the development of new treatment strategies.
Literatur
1.
Zurück zum Zitat Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol . 1996, 14: 2197-2205.PubMed Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol . 1996, 14: 2197-2205.PubMed
2.
Zurück zum Zitat Hanahan D, Weinberg RA: The hallmarks of cancer. Cell . 1999, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRef Hanahan D, Weinberg RA: The hallmarks of cancer. Cell . 1999, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRef
3.
Zurück zum Zitat Callahan R, Campbell G: Mutation in human breast cancer: an overview. J Natl Cancer Inst. 1989, 81: 1780-1786.CrossRefPubMed Callahan R, Campbell G: Mutation in human breast cancer: an overview. J Natl Cancer Inst. 1989, 81: 1780-1786.CrossRefPubMed
4.
Zurück zum Zitat Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the Her-2/NEU proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712.CrossRefPubMed Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the Her-2/NEU proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712.CrossRefPubMed
5.
Zurück zum Zitat Band V: The role of retinoblastoma and p53 tumor suppressor pathways in human mammary epithelial cell immortilization. Int J Oncol. 1998, 12: 499-507.PubMed Band V: The role of retinoblastoma and p53 tumor suppressor pathways in human mammary epithelial cell immortilization. Int J Oncol. 1998, 12: 499-507.PubMed
6.
Zurück zum Zitat Harley CB, Kim NW: Telomerase and cancer. Important Adv Oncol. 1996, 12: 57-67. Harley CB, Kim NW: Telomerase and cancer. Important Adv Oncol. 1996, 12: 57-67.
7.
Zurück zum Zitat Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000, 21: 505-515. 10.1093/carcin/21.3.505.CrossRefPubMed Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000, 21: 505-515. 10.1093/carcin/21.3.505.CrossRefPubMed
8.
Zurück zum Zitat Curran S, Murray GI: Matrix metalloproteinases in tumor invasion and metastasis. J Pathol. 1999, 189: 300-308. 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.3.CO;2-3.CrossRefPubMed Curran S, Murray GI: Matrix metalloproteinases in tumor invasion and metastasis. J Pathol. 1999, 189: 300-308. 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.3.CO;2-3.CrossRefPubMed
9.
Zurück zum Zitat Dennis JW, Granovsky M, Warren CE: Glycoprotein glycosylation and cancer progression. Biochem Biophys Acta. 1999, 1473: 21-34. 10.1016/S0304-4165(99)00167-1.CrossRefPubMed Dennis JW, Granovsky M, Warren CE: Glycoprotein glycosylation and cancer progression. Biochem Biophys Acta. 1999, 1473: 21-34. 10.1016/S0304-4165(99)00167-1.CrossRefPubMed
10.
Zurück zum Zitat Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW: Suppression of tumor growth and metastsis in Mgat5-deficient mice. Nat Med. 2000, 6: 306-312. 10.1038/73163.CrossRefPubMed Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW: Suppression of tumor growth and metastsis in Mgat5-deficient mice. Nat Med. 2000, 6: 306-312. 10.1038/73163.CrossRefPubMed
11.
Zurück zum Zitat Cummings RD, Trowbridge IS, Kornfeld S: A mouse lymphoma cell line resistant to the leukoaglutinating lectin from Phaseolus vulgaris is deficient in UDP-GlcNAc: alpha-D-mannoside beta-1,6-N-acetylglucosaminyltransferase. J Biol Chem. 1982, 257: 13421-13427.PubMed Cummings RD, Trowbridge IS, Kornfeld S: A mouse lymphoma cell line resistant to the leukoaglutinating lectin from Phaseolus vulgaris is deficient in UDP-GlcNAc: alpha-D-mannoside beta-1,6-N-acetylglucosaminyltransferase. J Biol Chem. 1982, 257: 13421-13427.PubMed
12.
Zurück zum Zitat Buck CA, Glick MC, Warren L: Effect of growth on the glycoproteins from the surface of control and Rous sarcoma virus transformed hamster cells. Science. 1971, 172: 169-174.CrossRefPubMed Buck CA, Glick MC, Warren L: Effect of growth on the glycoproteins from the surface of control and Rous sarcoma virus transformed hamster cells. Science. 1971, 172: 169-174.CrossRefPubMed
13.
Zurück zum Zitat Dennis JW, Kosh K, Bryce DM, Breitman ML: Oncogenes conferring metastatic potential induce increased branching of Asn-linked oligosaccharides in rat2 fibroblasts. Oncogene. 1989, 4: 853-860.PubMed Dennis JW, Kosh K, Bryce DM, Breitman ML: Oncogenes conferring metastatic potential induce increased branching of Asn-linked oligosaccharides in rat2 fibroblasts. Oncogene. 1989, 4: 853-860.PubMed
14.
Zurück zum Zitat Le Marer N, Laudet V, Svensson EC, Cazlaris H, Van Hille B, Lagrou C, Stehelin D, Montreuil J, Verbert A, Delannoy P: The c-Ha-ras oncogene induces increased expression of beta-galactoside alpha-2,6-sialyltransferase in rat fibroblast (FR3T3) cells. Glycobiology. 1992, 2: 49-56.CrossRefPubMed Le Marer N, Laudet V, Svensson EC, Cazlaris H, Van Hille B, Lagrou C, Stehelin D, Montreuil J, Verbert A, Delannoy P: The c-Ha-ras oncogene induces increased expression of beta-galactoside alpha-2,6-sialyltransferase in rat fibroblast (FR3T3) cells. Glycobiology. 1992, 2: 49-56.CrossRefPubMed
15.
Zurück zum Zitat Demetriou M, Nabi IR, Coppolino M, Dedhar S, Dennis JW: Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J Cell Biol. 1995, 130: 383-392.CrossRefPubMed Demetriou M, Nabi IR, Coppolino M, Dedhar S, Dennis JW: Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J Cell Biol. 1995, 130: 383-392.CrossRefPubMed
16.
Zurück zum Zitat Seelentag WK, Li WP, Schmitz SF, Metzger U, Aeberhard P, Heitz PU, Roth J: Prognostic value of β1,6-branched oligosaccharides in human colorectal cancer. Cancer Res. 1998, 58: 5559-5564.PubMed Seelentag WK, Li WP, Schmitz SF, Metzger U, Aeberhard P, Heitz PU, Roth J: Prognostic value of β1,6-branched oligosaccharides in human colorectal cancer. Cancer Res. 1998, 58: 5559-5564.PubMed
17.
Zurück zum Zitat Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS: β-1,6 branching of Apn-linked oligosaccharides is directly associated with metastasis. Science. 1987, 236: 582-585.CrossRefPubMed Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS: β-1,6 branching of Apn-linked oligosaccharides is directly associated with metastasis. Science. 1987, 236: 582-585.CrossRefPubMed
18.
Zurück zum Zitat Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW: β-1,6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res. 1991, 51: 718-723.PubMed Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW: β-1,6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res. 1991, 51: 718-723.PubMed
19.
Zurück zum Zitat Chen L, Zhang W, Fregien N, Pierce M: The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyl transferase V and expression of its cell surface oligosaccharide products. Oncogene . 1998, 17: 2087-2093. 10.1038/sj/onc/1202124.CrossRefPubMed Chen L, Zhang W, Fregien N, Pierce M: The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyl transferase V and expression of its cell surface oligosaccharide products. Oncogene . 1998, 17: 2087-2093. 10.1038/sj/onc/1202124.CrossRefPubMed
20.
Zurück zum Zitat Guy CT: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992, 12: 954-961.CrossRefPubMedPubMedCentral Guy CT: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992, 12: 954-961.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Metzler M, Gertz A, Sarkar M, Schachter H, Schrader JW, Marth JD: Complex asparagine-linked oligosaccharides are required for morphogenic events during post implantation development. EMBO J. 1994, 13: 2056-2065.PubMedPubMedCentral Metzler M, Gertz A, Sarkar M, Schachter H, Schrader JW, Marth JD: Complex asparagine-linked oligosaccharides are required for morphogenic events during post implantation development. EMBO J. 1994, 13: 2056-2065.PubMedPubMedCentral
22.
Zurück zum Zitat Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Risks of cancer in BRCA1 mutation carriers. Lancet. 1994, 343: 692-695. 10.1016/S0140-6736(94)91578-4.CrossRefPubMed Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Risks of cancer in BRCA1 mutation carriers. Lancet. 1994, 343: 692-695. 10.1016/S0140-6736(94)91578-4.CrossRefPubMed
23.
Zurück zum Zitat Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Manko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR: Localization of a breast cancer susceptibility gene BRCA-2 to chromosome 13q12-13. Science. 1994, 2655: 2088-2090.CrossRef Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Manko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR: Localization of a breast cancer susceptibility gene BRCA-2 to chromosome 13q12-13. Science. 1994, 2655: 2088-2090.CrossRef
Metadaten
Titel
Metastases: the glycan connection
verfasst von
Christine Couldrey
Jeffrey E Green
Publikationsdatum
01.10.2000
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 5/2000
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr75

Weitere Artikel der Ausgabe 5/2000

Breast Cancer Research 5/2000 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.